Advertisement

Gastric Cancer

, Volume 6, Supplement 1, pp 45–49 | Cite as

Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer

  • Hideo Baba
  • Manabu Yamamoto
  • Kazuya Endo
  • Yasuharu Ikeda
  • Yasushi Toh
  • Shunji Kohnoe
  • Takeshi Okamura
Article

Abstract

Several chemotherapy regimens used against advanced gastric cancer have been studied extensively over the decades in an attempt to further improve the prognosis of patients. To date, no standard chemotherapeutic regimens have been established worldwide. S-1 (TS-1®), a combination of ftorafur and two modulators, gimestat (CDHP) and oxonic acid, in a molar ratio of 1 : 0.4 : 1, has been widely used in Japan for the treatment of advanced gastric cancer, and much attention has been paid to attempts to increase its antitumor effect by combining it with other chemotherapeutic drugs. We treated 12 patients with advanced gastric cancer with 80 mg/m2 of S-1 for 21 days and 60 mg/m2 of cisplatin (CDDP) on day 8 every 5 weeks. The treatment was continued until disease progression, unacceptable toxicity, or the patient's refusal. Eight out of 12 evaluable patients achieved a partial response (PR), with a response rate of 66.7%. The incidence of grade 3 or 4 adverse effects, including myelosuppression and gastrointestinal toxicities, was 16.6%. None of the patients treated with this regimen died of adverse effects and none required hospitalization for the toxicity. We conclude that the combination of S-1 and CDDP seems to have a high therapeutic index, enhancing the antitumor effect of S-1 while maintaining modest adverse effects, thus suggesting the possible use of this combination based at the outpatient clinic (apart from a short stay in hospital during the infusion of CDDP with hydration). Further study with a large number of patients may be needed to confirm the combination of S-1 and CDDP to be an appropriate first-line chemotherapy for gastric cancer.

Key words

Chemotherapy Gastric cancer S-1 CDDP 

References

  1. 1.
    Mayer RJ. Newer cytotoxic agents for advanced colon cancer. ASCO Educational Book. 2000. p. 625–30Google Scholar
  2. 2.
    Heggie, GC, Sommadossi, JP, Cross, DS, Huster, WJ, Diasio, RB 1987Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bileCancer Res4720036Google Scholar
  3. 3.
    Diasio, RB 1998The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacologyOncology12237PubMedGoogle Scholar
  4. 4.
    Shirasaka, T, Nakano, K, Takechi, T, Satake, H, Uchida, J, Fujioka, A,  et al. 1996Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude ratsCancer Res5626026PubMedGoogle Scholar
  5. 5.
    Shirasaka, T, Shimamoto, Y, Fukushima, M 1993Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res5340049PubMedGoogle Scholar
  6. 6.
    Takechi, T, Nakano, K, Uchida, J, Mita, A, Toko, K, Takeda, S,  et al. 1997Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in ratsCancer Chemother Pharmacol3920511PubMedGoogle Scholar
  7. 7.
    Hirata, K, Horikoshi, N, Aibe, K, Okazaki, M, Denno, R, Sasaki, K,  et al. 1999Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drugClin Cancer Res520005PubMedGoogle Scholar
  8. 8.
    Takiuchi, H, Ajani, JA 1998Uracil-tegafur in gastric carcinoma: a comprehensive reviewJ Clin Oncol16287785PubMedGoogle Scholar
  9. 9.
    Taguchi, T, Inuyama, Y, Kanamaru, R, Hasegawa, K, Akazawa, S, Niitani, H,  et al. 1997Phase I study of S-1Jpn J Cancer Chemother24225364Google Scholar
  10. 10.
    Sakata, Y, Ohtsu, A, Horikoshi, N, Sugimachi, K, Mitachi, Y, Taguchi, T 1998Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patientsEur J Cancer34171520PubMedCrossRefGoogle Scholar
  11. 11.
    Sugimachi, K, Maehara, Y, Horikoshi, N, Shimada, Y, Sakata, Y, Mitachi, Y,  et al. 1999An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancersOncology5720210PubMedCrossRefGoogle Scholar
  12. 12.
    Koizumi, W, Kurihara, M, Nakano, S, Hasegawa, K 2000The S-1 Gastrointestinal Cancer Study Group. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancerOncology581917PubMedCrossRefGoogle Scholar
  13. 13.
    Ohtsu, A, Boku, N, Nagashima, F, Koizumi, W, Tanabe, S, Saigenji, K,  et al. 2001A phase I/II study of S-1 plus cisplatin (CDDP) in patients with advanced gastric cancer (abstract)Proc ASCO20165Google Scholar
  14. 14.
    Society, Japan 1993for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapyJ Jpn Soc Cancer Ther2810130Google Scholar
  15. 15.
    The Meta-Analysis Group in Cancer1998Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancerJ Clin Oncol163018Google Scholar
  16. 16.
    Lowy, AM, Mansfield, PF, Leach, SD, Pazdur, R, Dumas, P, Ajani, JA 1999Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancerAnn Surg2293038PubMedCrossRefGoogle Scholar

Copyright information

© International and Japanese Gastric Cancer Associations 2003

Authors and Affiliations

  • Hideo Baba
    • 1
  • Manabu Yamamoto
    • 1
  • Kazuya Endo
    • 1
  • Yasuharu Ikeda
    • 1
  • Yasushi Toh
    • 1
  • Shunji Kohnoe
    • 1
  • Takeshi Okamura
    • 1
  1. 1.Department of Gastroenterologic SurgeryNational Kyushu Cancer CenterFukuokaJapan

Personalised recommendations